Christopher Beene
Family Medicine · McAlester, OKNPI 1740476951
Payments from drug & device makers
Across 273 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$732
- AbbVie$668
- GSK$487
- Boehringer Ingelheim$248
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$211
- Lilly USA, LLC$197
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,23795%
- Education$2125%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $732 |
| AbbVie(2 entities) | 44 | $668 |
| GSK | 36 | $487 |
| Boehringer Ingelheim | 12 | $248 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $211 |
| Lilly USA, LLC | 13 | $197 |
| Amgen | 11 | $192 |
| Mylan Specialty L.p. | 9 | $178 |
| Pfizer | 11 | $173 |
| Teva Pharmaceuticals USA, Inc. | 5 | $144 |
| Eisai Inc. | 6 | $136 |
| AstraZeneca | 9 | $135 |
| Antares Pharma, Inc. | 6 | $121 |
| Sanofi-aventis U.S. LLC | 8 | $107 |
| Johnson & Johnson | 6 | $97 |
| Astellas Pharma US Inc | 1 | $95 |
| Novartis | 4 | $73 |
| Bayer | 4 | $52 |
| Amarin Pharma, Inc. | 2 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $46 |
| Gilead | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Biogen | 1 | $18 |
| QOL Medical, LLC | 1 | $17 |
| Fisher & Paykel Healthcare Inc | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Alk-abello, Inc | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $11 |
How this compares
$4,449 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 120 | $130,288 |
| MounjaroTirzepatide | 48 | $46,808 |
| JanuviaSitagliptin Phosphate | 54 | $27,380 |
| JardianceEmpagliflozin | 30 | $25,263 |
| EliquisApixaban | 33 | $22,900 |
| LinzessLinaclotide | 35 | $22,009 |
| GemtesaVibegron | 19 | $16,386 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $13,730 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $13,710 |
| XareltoRivaroxaban | 17 | $12,608 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $10,823 |
| Spiriva RespimatTiotropium Bromide | 16 | $8,323 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 339 | $8,003 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $7,867 |
| VerquvoVericiguat | 11 | $6,620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $732 | $130,288120 claims |
| Lilly USA, LLCMounjaro | $197 | $46,80848 claims |
| MerckJanuvia, Verquvo | $17 | $34,00065 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $248 | $33,58646 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $487 | $32,42063 claims |
| PfizerEliquis | $173 | $22,90033 claims |
| AbbVieLinzess | $668 | $22,00935 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $25 | $16,38619 claims |
| Johnson & JohnsonXarelto | $97 | $12,60817 claims |
| AstraZenecaBrilinta | $135 | $4,43811 claims |
| Eisai Inc.Dayvigo | $136 | $3,79212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in McAlester
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.